July 30, 2025 – Porton Advanced, a leading cell and gene therapy CDMO, and CellStore, an innovator in cryopreservation solutions, announced a strategic collaboration to advance cryopreservation media technology for cell therapy manufacturing. The partnership aims to enhance the performance and cost-effectiveness of cryopreservation solutions, facilitating the development and commercialization of cell-based therapies.
Safe and effective cryopreservation technology is critical across all stages of cell therapy manufacturing, from seed cells to final drug products. High-quality cryopreservation media not only improve cell viability and therapeutic efficacy but also streamline R&D timelines and production processes.
Under this agreement, CellStore will supply Porton Advanced with high-efficiency, GMP-compliant cryopreservation solutions tailored for diverse cell types and automated production systems. The companies will also collaborate to develop customized formulations for challenging cell therapy applications and advance regulatory filings of pharmaceutical excipients to accelerate time-to-market.
With the global cell therapy market expanding rapidly, reducing manufacturing costs remains a key challenge. As a premier CDMO in China, Porton Advanced has supported dozens of IND filings and clinical-stage productions across plasmids, viral vectors, mRNA, and cell therapies. By integrating CellStore's cryopreservation technology, the partnership will secure supply chain stability, lower manufacturing cost and enhance accessibility to cell therapy products.
"Collaborating with CellStore allows us to deliver more cost-effective solutions to our clients," said Andrew Chen, CFO of Porton Advanced. "Their innovative cryopreservation technology not only enhances cell recovery rates but also simplifies manufacturing workflows, ultimately delivering higher competitive CDMO services for our global clients."
Dr. Sun Yuling, CEO of CellStore, added: "CellStore is dedicated to developing reliable, high-performance biological sample cryopreservation solutions. This partnership with Porton Advanced will help accelerate the development of life-saving cell therapies worldwide."
CellStore Biotechnology Co., Ltd. ("CellStore") is an innovative enterprise specialized in the R&D and production of cryopreservation media for bio-samples. We have built a world-leading technology platform for cryopreservation of biological samples.
Based on over a decade of innovative research, our experts from the Chinese Academy of Sciences have developed a groundbreaking “ice controlling cryopreservation technology". Relying on a fully independent research and development ice control material synthesis library, we have developed and produced a variety of dimethyl sulfoxide (DMSO) free, serum-free, protein-free and animal-free” cryopreservation media containing mere PRC Pharmacopoeia ingredients to provide cryopreservation solutions tailored to the emerging biopharmaceutical industry.
Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced's headquarter is located in Cranbury, New Jersey, with two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, investigator-initiated clinical trials (IITs), Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.
Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sqft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 18 global IND approvals from NMPA, FDA, and Medsafe, with 6 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.
Porton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and Africa
Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy
Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs
Porton Advanced’s End-to-End CDMO Solutions Accelerates IND Approval of Tasly’s Innovative Dual-Targeting CAR-T Therapy
Porton Advanced Supports Immunofoco’s Second IND Clearance from China’s CDE for EpCAM CAR-T Therapy in Solid Tumors
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development